Answers are grounded in this paper and cite their sources.
This study suggests that nonconfluent panretinal photocoagulation for aggressive posterior retinopathy of prematurity infants who have received intravitreal bevacizumab may be safe and effective. This study's strengths include a sizeable sample size, long-term follow-up of nearly 4 years, and consistency in treatment among patients by a single, experienced retinopathy of prematurity specialist.
No takes yet. Share an insight, caveat, or question.
Mammo et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: